AMARIN CORP PLC\UK Debt Instrument, Convertible, Carrying Amount of Equity Component
AMARIN CORP PLC\UK (AMRN) had Debt Instrument, Convertible, Carrying Amount of Equity Component of $11.50 million as of 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Notes › Debt Instruments
us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent · last filed 2017-03-01
- 2016-12-31: Debt Instrument, Convertible, Carrying Amount of Equity Component $11.50M.
- 2016-09-30: Debt Instrument, Convertible, Carrying Amount of Equity Component $11.50M.
- 2016-06-30: Debt Instrument, Convertible, Carrying Amount of Equity Component $11.50M.
- 2016-03-31: Debt Instrument, Convertible, Carrying Amount of Equity Component $11.50M.
| Period end | Debt Instrument, Convertible, Carrying Amount of Equity Component |
|---|---|
| 2016-12-31 | $11.50M 10-K · filed 2017-03-01 |
| 2016-09-30 | $11.50M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $11.50M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $11.50M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $11.50M 10-K · filed 2017-03-01 |
| 2014-12-31 | $12.80M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |